Vancouver, British Columbia – December 11, 2024 –TheNewswire –MindBio Therapeutics Corp.(the “Company” or “MindBio”) (CSE: MBIO) (Frankfurt:WF6) wishes to provide an update to its shareholders on the impact of the strike by the Canadian Union of Postal Workers on the Company’s ability to comply with its obligations to deliver shareholders its financial statements and related disclosure and proxy-related materials in respect of the Company’s annual general meeting of shareholders scheduled to be held at Suite 2200, 885 West Georgia Street, Vancouver, British Columbia, Canada on the 18thday of December, 2024 at 2:00 p.m. (Vancouver time) (the “Meeting”)
As a result of the strike, and pursuant to CSA Coordinated Blanket Order 51-931Temporary Exemption from requirements in National Instrument 51-102 Continuous Disclosure Requirements and National Instrument 54-101 Communication with Beneficial Owners of Securities of a Reporting Issuer to send certain proxy-related materials during a postal strike(the “Blanket Order”), the Company is advising shareholders that:
1.At the Meeting, shareholders will be asked to vote on the following matters, all as more particularly described in the Company’s information circular for the Meeting:
a)to appoint MNP LLP as auditor of the Company for the ensuing year and authorize the board of directors to fix the remuneration of the auditor;
b)to fix the number of the directors of the Company for the ensuing year at three (3);
c)to elect directors to hold office for the ensuing year; and
d)to transact such other business as may properly be transacted at the Meeting or at any adjournment thereof.
2.Electronic versions of the Company’s information circular, form of proxy and all other proxy-related materials for the Meeting (collectively, the “Meeting Materials”), as applicable, have been filed and are available on the Company’s profile on the SEDAR+ website at www.sedarplus.ca and are also posted on the Company’s website athttps://www.mindbiotherapeutics.com/investors.
3.The Company has satisfied all of the conditions to rely on, and is relying on, the exemption provided by the Blanket Order from the requirement to send proxy-related materials to its shareholders.
4.The Company will provide copies of the applicable Meeting Materials by email to each entitled shareholder who requests same while the strike is ongoing, at no charge.
5.If you are a registered shareholder, please contact the Company’s Transfer Agent, Odyssey Trust Company, at www.odysseytrust.com/ca-en/help/ to submit a request for your individual control number to vote by selecting “I am a Shareholder” then “Obtain Proxy Control Number” to cast your vote for the upcoming Meeting.
6.Beneficial shareholders are shareholders who hold their investment through a brokerage house, depository company or other intermediary. Beneficial shareholders should contact their brokerage house or depository company or other intermediary and ask to obtain their voting control number and the steps of how to vote, which could include internet voting, completing a form of proxy and emailing it, directing your broker over the phone on how you wish to vote or some other method as described by your brokerage house or depository company.
7.Copiesof the Company’s audited consolidated financial statements of the Company as at and for the financial year ended June 30, 2024 and 2023 and related management discussion and analysis as well as interim financial statements and related management discussion and analysis are available under the Company’s SEDAR+ profile. Any shareholders who would like to receive paper copies of the financial statements and MD&A should contact the Company at the telephone number or email provided below.
8.In all cases, shareholders’ votes must be received not later than 2:00 p.m. (Vancouver time) on Monday, December 16, 2024 or not less than 48 hours (excluding Saturdays, Sundays and holidays) before the time for the holding of the Meeting or any adjournment thereof.
Shareholders with questions on voting or who would like to request electronic copies ofMeeting Materials may contact Odyssey at 1-888-290-1175 or email shareholder@odysseytrust.com, or may contact the Company at the contact information set out below.
Receive our latest updates here: https://www.mindbiotherapeutics.com/get-updates
About MindBio Therapeutics
MindBio is a leading biotech/biopharma company focused on creating novel and emerging treatments for mental health conditions and is conducting world first take-home Microdosing (MB22001) human clinical trials. MB22001 is MindBio’s lead candidate drug, a proprietary titratable form of Lysergic Acid Diethylamide (LSD) designed for take-home microdosing.
MindBio is a leader in microdosing of psychedelic medicines and is advancing its drug and technology protocols through clinical trials. MindBio has developed a multi-disciplinary platform for developing treatments and is involved in psychedelic medicine development and digital therapeutics, has completed Phase 1 clinical trials in 80 healthy participants and has completed a Phase 2a clinical trial in patients with Major Depressive Disorder, both trials with positive top line data reported. Currently underway are two Phase 2B trials, one in cancer patients experiencing existential distress and another in patients with Major Depressive Disorder. The Company is also approved for multiple Phase 1/Phase 2B trials in women’s health. MindBio invests in research that forms the basis for developing novel and clinically proven treatments including digital technologies and interventions to treat debilitating health conditions such as depression, anxiety and other related mental health conditions.
For further information, please contact:
Justin Hanka
Chief Executive Officer
Tel: +61 433140886
Email: justin@mindbiotherapeutics.com
For media inquiries, please contact
Kristina Spionjak
Email :pr@hlthcommunications.com
Receive our latest updates here: https://www.mindbiotherapeutics.com/get-updates